Today, as part of a national initiative funded by The John A. Hartford Foundation (JAHF), the national, independent nonprofit FAIR Health launched a new shared decision-making tool for Alzheimer's ...

Retired electrician Joe Walsh in December became the first Alzheimer’s patient to try a nasal spray used to treat other ...

Bishop asked about upcoming events. Missling outlined the anticipated schizophrenia trial readout for ANAVEX 3-71 in the first half of 2025, the detailed ATTENTION-AD data presentation in April, and ...

Sanofi-backed Abcuro has secured $200 million in series C funds to power its anti-KLRG1 antibody through a phase 2/3 muscle ...

Leqembi (lecanemab) and Kisunla (donanemab) are proven to slow cognitive and functional decline by 27 and 35%, respectively.

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

Monoclonal antibodies have emerged as a promising approach in the fight against Alzheimer's disease, offering hope for slowing its progression. T ...

The drug is designed to reduce inflammation in the brain and has been used on MS, cancer and migraine headaches.